Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kailash Mosalpuria

Hematology & Oncology Lincoln, NE Medical Doctor

NPI 1669636643 CMS profile 1380826

4004 Pioneer Woods Dr, Lincoln, NE 68506

Open in the dashboard

General payments

$17,087

126 records reported · program years 2019–2025

Research payments

$1,123

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,211,445 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kailash Mosalpuria of Lincoln, NE is reported in the CMS Open Payments database as having received $17,087 across 126 general payments and $1,123 in research payments paid to them. Separately, studies naming them as principal investigator received $4,211,445 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,618 55
2025 Research $222 5
2024 General $480 33
2023 General $238 13
2023 Research $902 1
2022 General $157 3
2021 General $40 3
2020 General $1,383 4
2019 General $1,171 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kailash Mosalpuria
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Kailash Mosalpuria were reported at $13,618. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Kailash Mosalpuria Hematology & Oncology median Middle half National median
2019 $1,171 $529 $121–$2,516 $163
2020 $1,383 $339 $82–$2,213 $114
2021 $40 $263 $49–$1,965 $132
2022 $157 $416 $103–$2,395 $149
2023 $238 $542 $125–$2,646 $160
2024 $480 $692 $141–$3,008 $164
2025 $13,618 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Geron Corporation $3,582 12 payments
  2. Pfizer Inc. $3,181 17 payments
  3. E.R. Squibb & Sons, L.L.C. $2,514 3 payments
  4. Eisai Inc. $2,461 3 payments
  5. Novartis Pharmaceuticals Corporation $2,288 5 payments
  6. Rigel Pharmaceuticals, Inc. $1,017 2 payments
  7. Astellas Pharma US Inc $335 2 payments
  8. Genentech USA, Inc. $171 8 payments
  9. AbbVie, Inc. $153 7 payments
  10. Janssen Biotech, Inc. $150 4 payments
  11. Other $1,236 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,770 5 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,213 3 payments
  3. Food and Beverage $1,965 103 payments
  4. Travel and Lodging $771 4 payments
  5. Education $369 11 payments
Products named General payments · program years 2019–2025
  1. IMETELSTAT $3,567 11 payments
  2. Lenvima $2,461 3 payments
  3. ELREXFIO $2,117 2 payments
  4. Tavalisse $1,017 2 payments
  5. IBRANCE $1,011 9 payments
  6. XOSPATA $335 2 payments
  7. KEYTRUDA $103 8 payments
  8. EPKINLY $102 4 payments
  9. ERLEADA $100 1 payment
  10. Yescarta $96 2 payments
  11. Other $1,734 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $902 1 payment
  2. AbbVie, Inc. $222 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,289

Median for Medical Oncology: 414

Drug cost

$6,316,997

Median for Medical Oncology: $849,427

Branded share of claims

44%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jakafi Ruxolitinib Phosphate Brand 88 $1,468,269
Pomalyst Pomalidomide Brand 53 $1,002,103
Lenalidomide Generic 73 $912,704
Calquence Acalabrutinib Maleate Brand 53 $782,690
Revlimid Lenalidomide Brand 38 $605,666
Nubeqa Darolutamide Brand 27 $363,103
Ninlaro Ixazomib Citrate Brand 28 $358,155
Venclexta Venetoclax Brand 28 $355,211
Brukinsa Zanubrutinib Brand 13 $195,081
Xtandi Enzalutamide Brand 12 $161,029

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 181 billing codes

Paid by Medicare

$6,406,112

Of which drugs: $6,019,650

Medicare patients

865

Average age 75

Services billed

342,878

455 women, 410 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 49%
Arthritis 48%
Chronic kidney disease 35%
Diabetes 31%
Ischemic heart disease 29%
Heart failure 28%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 26 25,560 $1,000,378
Injection, pembrolizumab, 1 mg J9271 Office 31 21,800 $974,979
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 35 12,761 $456,844
Injection, nivolumab, 1 mg J9299 Office 13 13,940 $341,713
Injection, denosumab, 1 mg J0897 Office 53 10,920 $225,396
Injection, romiplostim, 10 micrograms J2796 Office 11 2,305 $178,648
Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130 Office 27 768 $119,188
Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Office 13 2,230 $102,380
Injection, ferric carboxymaltose, 1 mg J1439 Office 60 70,500 $61,004
Injection, aprepitant, 1 mg J0185 Office 48 18,460 $24,899

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $35
  • AstraZeneca Pharmaceuticals LP $26
$61 — —
EPKINLY
  • AbbVie, Inc. $48
$48 — —
IBRANCE
  • PFIZER INC. $37
$37 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $30
$30 — —
ELAHERE
  • AbbVie, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record